These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 6824588)

  • 1. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis.
    Rondeau E; Solal-Celigny P; Dhermy D; Vroclans M; Brousse N; Bernard JF; Boivin P
    Br J Haematol; 1983 Mar; 53(3):467-75. PubMed ID: 6824588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia.
    Michiels JJ
    Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between autoimmunity and agnogenic myeloid metaplasia.
    Ben-Chetrit E; Gross DJ; Okon E; Levo Y
    Scand J Haematol; 1983 Nov; 31(5):410-2. PubMed ID: 6606213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunitary disorders during myeloid splenomegaly with myelofibrosis].
    Boivin P; Hakim J; Kahn A; Bernard JF
    Nouv Presse Med; 1972 Apr; 1(14):960. PubMed ID: 5019303
    [No Abstract]   [Full Text] [Related]  

  • 5. [Serum immunological abnormalities in myeloid splenomegaly and myelosclerosis].
    Boivin P
    Rev Roum Med Intern; 1973; 10(3):170-7. PubMed ID: 4123073
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunoglobulin levels in polycythemia vera, erythrocytosis, secondary polycythemia and myelofibrosis.
    Meytes D; Shacked N; Padeh B; Czerniak P; Pinkhas J; Ramot B
    Isr J Med Sci; 1972 Jul; 8(7):925-31. PubMed ID: 4115562
    [No Abstract]   [Full Text] [Related]  

  • 7. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
    Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
    Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis.
    Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A
    Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases.
    Brenner B; Nagler A; Tatarsky I; Hashmonai M
    Arch Intern Med; 1988 Nov; 148(11):2501-5. PubMed ID: 3190384
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
    Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
    Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT).
    Mesa RA; Verstovsek S; Cervantes F; Barosi G; Reilly JT; Dupriez B; Levine R; Le Bousse-Kerdiles MC; Wadleigh M; Campbell PJ; Silver RT; Vannucchi AM; Deeg HJ; Gisslinger H; Thomas D; Odenike O; Solberg LA; Gotlib J; Hexner E; Nimer SD; Kantarjian H; Orazi A; Vardiman JW; Thiele J; Tefferi A;
    Leuk Res; 2007 Jun; 31(6):737-40. PubMed ID: 17210175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Tefferi A
    Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypocholesterolemia and other lipoprotein disorders in myelofibrosis].
    Kiss A; Telek B; Rák K
    Orv Hetil; 1994 Nov; 135(48):2643-6. PubMed ID: 7808738
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune complexes in myeloproliferative disorders.
    Lewis CM; Pegrum GD
    Lancet; 1977 Dec; 2(8049):1151-3. PubMed ID: 73061
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Excess of blood group B in primary myelofibrosis.
    Jaff MS; O'Briain DS
    Vox Sang; 1987; 52(3):250-3. PubMed ID: 3111093
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic parameters in myeloid metaplasia: agnogenic versus postpolycythemic.
    Meytes D; Katz D; Ramot B
    Isr J Med Sci; 1976 Jun; 12(6):534-42. PubMed ID: 955869
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Erythrocytic and immunologic abnormalities in myeloid splenomegaly].
    Dao C; Harousseau JL; de Carbonniéres C; Bousser J; Bilski-Pasquier G
    Nouv Rev Fr Hematol Blood Cells; 1977; 18(3):619-26. PubMed ID: 600781
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data.
    Thiele J; Zankovich R; Steinberg T; Kremer B; Fischer R; Diehl V
    Acta Haematol; 1989; 81(4):192-202. PubMed ID: 2474228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased circulating neutrophils with surface receptor activity for immunoglobulin G in polycythemia vera and myeloid metaplasia.
    Gilbert HS; Goldberg R; Ward L
    Blood; 1979 Jun; 53(6):1106-13. PubMed ID: 444652
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.